MED Valuation

Medifast Inc

Add to Watchlist

Advanced Chart

11.460

-0.17(-1.462%)1D

MED Relative Valuation

MED's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MED is overvalued; if below, it's undervalued.

Historical Valuation

Medifast Inc (MED) is now in the Fair zone, suggesting that its current forward PS ratio of 11.63 is considered Fairly compared with the five-year average of 11.70. The fair price of Medifast Inc (MED) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：11.45

Fair

-7.74

Trailing

Forward

3.71

EV/EBITDA

Medifast Inc. (MED) has a current EV/EBITDA of 3.71. The 5-year average EV/EBITDA is 7.12. The thresholds are as follows: Strongly Undervalued below -0.53, Undervalued between -0.53 and 3.30, Fairly Valued between 10.95 and 3.30, Overvalued between 10.95 and 14.77, and Strongly Overvalued above 14.77. The current Forward EV/EBITDA of 3.71 falls within the Historic Trend Line -Fairly Valued range.

1.43

EV/EBIT

Medifast Inc. (MED) has a current EV/EBIT of 1.43. The 5-year average EV/EBIT is 8.21. The thresholds are as follows: Strongly Undervalued below -18.10, Undervalued between -18.10 and -4.95, Fairly Valued between 21.36 and -4.95, Overvalued between 21.36 and 34.52, and Strongly Overvalued above 34.52. The current Forward EV/EBIT of 1.43 falls within the Historic Trend Line -Fairly Valued range.

11.46

Medifast Inc. (MED) has a current PS of 11.46. The 5-year average PS is 1.13. The thresholds are as follows: Strongly Undervalued below -1.45, Undervalued between -1.45 and -0.16, Fairly Valued between 2.43 and -0.16, Overvalued between 2.43 and 3.72, and Strongly Overvalued above 3.72. The current Forward PS of 11.46 falls within the Strongly Overvalued range.

0.00

P/OCF

Medifast Inc. (MED) has a current P/OCF of 0.00. The 5-year average P/OCF is 10.18. The thresholds are as follows: Strongly Undervalued below -1.23, Undervalued between -1.23 and 4.48, Fairly Valued between 15.89 and 4.48, Overvalued between 15.89 and 21.60, and Strongly Overvalued above 21.60. The current Forward P/OCF of 0.00 falls within the Undervalued range.

-8.13

P/FCF

Medifast Inc. (MED) has a current P/FCF of -8.13. The 5-year average P/FCF is 17.93. The thresholds are as follows: Strongly Undervalued below -20.45, Undervalued between -20.45 and -1.26, Fairly Valued between 37.13 and -1.26, Overvalued between 37.13 and 56.32, and Strongly Overvalued above 56.32. The current Forward P/FCF of -8.13 falls within the Undervalued range.

Medifast Inc (MED) has a current Price-to-Book (P/B) ratio of 0.56. Compared to its 3-year average P/B ratio of 2.92 , the current P/B ratio is approximately -80.96% higher. Relative to its 5-year average P/B ratio of 7.16, the current P/B ratio is about -92.22% higher. Medifast Inc (MED) has a Forward Free Cash Flow (FCF) yield of approximately 0.01%. Compared to its 3-year average FCF yield of 17.90%, the current FCF yield is approximately -99.97% lower. Relative to its 5-year average FCF yield of 12.51% , the current FCF yield is about -99.96% lower.

0.55

P/B

Median3y

2.92

Median5y

7.16

0.01

FCF Yield

Median3y

17.90

Median5y

12.51

Competitors Valuation Multiple

The average P/S ratio for MED's competitors is 7.16, providing a benchmark for relative valuation. Medifast Inc Corp (MED) exhibits a P/S ratio of 11.46, which is 59.97% above the industry average. Given its robust revenue growth of -36.21%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Forrester Research Inc

Resources Connection Inc

Performance Decomposition

Market capitalization of MED decreased by 41.74% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 113.31 to 574.29.

The secondary factor is the Revenue Growth, contributed -36.21%to the performance.

Overall, the performance of MED in the past 1 year is driven by P/E Change. Which is more unsustainable.

-36.21%

140.16M → 89.41M

Revenue Growth

-412.35%

0.81 → -2.53

Margin Expansion

406.82%

113.31 → 574.29

P/E Change

-41.74%